Therapeutic effect of multifunctional celastrol nanoparticles with mitochondrial alkaline drug release in breast cancer
Source abstract
Abstract
Mitochondria have been shown to play a variety of roles in tumorigenesis and progression, and thus present an attractive therapeutic target for cancer treatment. Herein, we developed multifunctional celastrol (cela) nanoparticles with mitochondrial alkaline drug release and feature a positive core and a negative outer layer. First, the mitochondria-targeting material, triphenyl phosphonium-tocopherol polyethylene glycol succinate (TPP-TPGS, TT), was synthesised, and TT/[email protected] nanoparticles (NPs) were prepared. Then, the positive charge on the surface was neutralised using tumor-targeting, pH-sensitive chondroitin sulfate-folic acid (CS-FA) to generate CS-FA/TT/[email protected] NPs. Characterisation revealed these NPs to be globular particles with smooth surfaces and an average diameter of 100 nm - characteristics that could enhance their uptake by 4T1 murine breast cancer cells. After CS-FA/TT/[email protected] NPs entered 4T1 cells, CS-FA was degraded and the positively charged TT/[email protected] NPs were exposed and able to target the mitochondria after performing lysosomal escape. Celastrol is released upon exposure of TT/[email protected] NPs to the alkaline mitochondrial environment, and assessment of mitochondrial respiration and membrane potential revealed celastrol to induce mitochondrial injury and damage. Exposure of 4T1 cells to these nanoparticles significantly upregulated proapoptotic protein expression in vitro, and generated robust anticancer effects in vivo. Together, these results indicate that CS-FA/TT/[email protected] NPs with mitochondrial alkaline drug release represent a promising advancement in breast cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Natural Compounds in Disease Treatment · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (42)
Show source-provided references
1. Cancer statistics, 2021, CA. Cancer
2. The American cancer society's facts & figures: 2020 edition
3. Lymphedema following breast cancer treatment and impact on quality of life: a review10.1016/j.critrevonc.2014.06.004 ↗
4. Nanotechnology-Based celastrol formulations and their therapeutic applications10.3389/fphar.2021.673209 ↗
5. Tripterine inhibits proliferation, migration and invasion of breast cancer MDA-MB-231 cells by up-regulating microRNA-15a10.1515/hsz-2018-0469 ↗
6. Anticancer effect of celastrol on human triple negative breast cancer: possible involvement of oxidative stress, mitochondrial dysfunction, apoptosis and PI3K/Akt pathways10.1016/j.yexmp.2015.03.031 ↗
7. Preparation, characterization and cytotoxic evaluation of inclusion complexes between celastrol with polyamine-modified β-cyclodextrins10.1007/s10847-019-00933-7 ↗
8. Mitochondria as new therapeutic targets for eradicating cancer stem cells: quantitative proteomics and functional validation via MCT1/2 inhibition10.18632/oncotarget.2789 ↗
9. Induction of mitochondrial cell death and reversal of anticancer drug resistance via nanocarriers composed of a triphenylphosphonium derivative of tocopheryl polyethylene glycol succinate10.1021/acs.molpharmaceut.9b00177 ↗
10. Celastrol: a review of useful strategies overcoming its limitation in anticancer application10.3389/fphar.2020.558741 ↗
11. Mitochondrial dynamics and its involvement in disease10.1146/annurev-pathmechdis-012419-032711 ↗
12. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis10.1186/s12951-019-0562-3 ↗
13. Dodecyl-TPP targets mitochondria and potently eradicates cancer stem cells (CSCs): synergy with FDA-approved drugs and natural compounds (vitamin C and berberine)10.3389/fonc.2019.00615 ↗
14. Triphenylphosphonium-conjugated glycol chitosan microspheres for mitochondria-targeted drug delivery10.1016/j.ijbiomac.2020.11.129 ↗
15. Factors affecting the clearance and biodistribution of polymeric nanoparticles10.1021/mp800051m ↗
16. Metabolism of nanomaterials in vivo: blood circulation and organ clearance10.1021/ar2003336 ↗
17. Elimination pathways of nanoparticles10.1021/acsnano.9b01383 ↗
18. Self-assembled nanomedicine combining a berberine derivative and doxorubicin for enhanced antitumor and antimetastatic efficacy via mitochondrial pathways10.1039/D1NR00032B ↗
19. Folic acid-peptide conjugates combine selective cancer cell internalization with thymidylate synthase dimer interface targeting10.1021/acs.jmedchem.0c02107 ↗
20. Mitochondrial alkaline pH-responsive drug release mediated by Celastrol loaded glycolipid-like micelles for cancer therapy10.1016/j.biomaterials.2017.07.036 ↗
21. Stepwise dual targeting and dual responsive polymer micelles for mitochondrion therapy10.1016/j.jconrel.2020.03.011 ↗
22. Self-activated cascade biocatalysis of glucose oxidase-polycation-iron nanoconjugates augments cancer immunotherapy10.1021/acsami.2c04894 ↗
23. ROS-responsive nano-drug delivery system combining mitochondria-targeting ceria nanoparticles with atorvastatin for acute kidney injury10.7150/thno.40395 ↗
24. A small-molecule based organic nanoparticle for photothermal therapy and near-infrared-IIb imaging10.1021/acsami.2c11706 ↗
25. NMR chemical shifts of trace impurities: industrially preferred solvents used in process and green chemistry10.1021/acs.oprd.5b00417 ↗
26. Nanocarriers' entry into the cell: relevance to drug delivery10.1007/s00018-009-0053-z ↗
27. pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer10.1186/s12951-021-00895-4 ↗
28. Intracellular trafficking of hyaluronic acid-chitosan oligomer-based nanoparticles in cultured human ocular surface cells
29. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors10.1073/pnas.151247498 ↗
30. Use of cyclodextrins for manipulating cellular cholesterol content10.1016/S0022-2275(20)34940-3 ↗
31. Increased non-quantal release of acetylcholine after inhibition of endocytosis by methyl-β-cyclodextrin: the role of vesicular acetylcholine transporter10.1016/j.neuroscience.2011.04.051 ↗
32. Mis-assembly of clathrin lattices on endosomes reveals a regulatory switch for coated pit formation10.1083/jcb.123.5.1107 ↗
33. Itinerary of high density lipoproteins in endothelial cells10.1016/j.bbalip.2015.11.004 ↗
34. Cetuximab-siRNA conjugate linked through cationized gelatin knocks down KRAS G12C mutation in NSCLC sensitizing the cells toward gefitinib10.1177/15330338211041453 ↗
35. Catabolism of chondroitin sulfate10.1515/cmble-2015-0011 ↗
36. The biosynthesis and catabolism of galactosaminoglycans10.1016/S1054-3589(05)53005-9 ↗
37. Rational construction of a mitochondrial targeting, fluorescent self-reporting drug-delivery platform for combined enhancement of endogenous ROS responsiveness10.1021/acsami.0c08336 ↗
38. Mitochondrial ROS1 increases mitochondrial fission and respiration in oral squamous cancer carcinoma10.3390/cancers12102845 ↗
39. A multifunctional nano-delivery system enhances the chemo-co-phototherapy of tumor multidrug resistance via mitochondrial-targeting and inhibiting P-glycoprotein-mediated efflux10.1039/D1TB01658J ↗
40. Perfluorooctane sulfonate induces apoptosis in lung cancer A549 cells through reactive oxygen species-mediated mitochondrion-dependent pathway10.1002/jat.2785 ↗
41. Aperture modulation of isoreticular metal organic frameworks for targeted antitumor drug delivery
42. Ligustrazine suppresses neuron apoptosis via the Bax/Bcl-2 and caspase-3 pathway in PC12 cells and in rats with vascular dementia10.1002/iub.1704 ↗